2018 Healthcare Revolution Innovation Award, we rose to 377th place in the ranking of the Largest Company by R&D Expenditures in 2021.
2018 Healthcare Revolution Innovation Award
In 2018, we wrote about what we have done over the years for the Healthcare Revolution Innovation Awards organized by Global Healthcare Resources from the United States.
• Increasing studies on rare diseases since 2010,
• Investing a significant portion of our revenues in R&D,
• Our efforts to disseminate service providers with free training,
• We are producing a significant part of our materials,
• Combining an academic structure with a company structure,
• Our research ranges from basic science to production,
• We talked about when we were founded, what we thought, what investments we made, our projects, the number of patients we looked at, the tests we set up, and the kits we developed for each patient who came to us.
We were selected as the “Best Innovator” among the 1000 participating companies. In the same year, we were invited to present our award in Orlando. However, as it coincided with the relocation of our center to the new building, we could not go and walk the red carpet for our award. But we celebrated without a red carpet with our team. This award was made with the efforts of all of us. I would like to thank all my colleagues who contributed to this process, which was created by everyone from the team responsible for the cleaning of Intergen, to the accounting, from the R&D unit to the physicians, and from the team that accepted the material to the laboratory team.
We are a very strong team together.
2018 R&D Top 500
In 2018, T.C. According to the data of the Ministry of Industry and Technology, we were
included in the list of the top 500 companies based on the R&D investments of the companies. As in the past, we continue our R&D investments today for the benefit of our country and our patients.
2021 R&D Top 500
We rose to 377th place in the ranking of the Largest Company by R&D Expenditures in 2021. Compared to 2018, when we first entered the list, we are 115 steps higher. We plan to increase our R&D investments by 40% in 2022. While we aim to continue to provide qualified services to our country in the fields of diagnosis, research, and application of genetic diseases, we aim to be among the top 250 companies in this ranking in 2024, when we will celebrate our 25th anniversary.